Moderna (MRNA) Research & Development (2018 - 2026)

Moderna (MRNA) has 9 years of Research & Development data on file, last reported at $649.0 million in Q1 2026.

• On a quarterly basis, Research & Development fell 24.18% year-over-year to $649.0 million in Q1 2026; TTM through Mar 2026 was $2.9 billion, a 32.54% decrease from a year earlier, with the FY2025 full-year figure at $3.1 billion, down 31.06% from the prior year.
• Research & Development for Q1 2026 stood at $649.0 million, down from $775.0 million in the prior quarter.
• Over the last five years, Research & Development for MRNA reached as high as $1.4 billion in Q4 2023 and fell as low as $554.0 million in Q1 2022.
• Historically, Research & Development has averaged $968.5 million across 5 years, with a median of $1.1 billion in 2024.
• Across the five-year window, Research & Development soared 104.15% in 2023 and tumbled 42.67% in 2025, its largest moves.
• Year by year, Research & Development stood at $1.2 billion in 2022, then increased by 16.1% to $1.4 billion in 2023, then slipped by 20.2% to $1.1 billion in 2024, then slumped by 30.93% to $775.0 million in 2025, then fell by 16.26% to $649.0 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $649.0 million in Q1 2026, $775.0 million in Q4 2025, and $801.0 million in Q3 2025.